{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:03:49Z","timestamp":1772809429612,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10096-019-03582-3","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:01:54Z","timestamp":1558537314000},"page":"1533-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients"],"prefix":"10.1007","volume":"38","author":[{"given":"Amulya","family":"Uppala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther A.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimple","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"3582_CR1","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103\u2013e120","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 4","key":"3582_CR2","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/382690","volume":"38","author":"D Paterson","year":"2004","unstructured":"Paterson D (2004) \u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38(Suppl. 4):S341\u2013S345","journal-title":"Clin Infect Dis"},{"key":"3582_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1086\/379709","volume":"37","author":"M Zervos","year":"2003","unstructured":"Zervos M, Hershberger E, Nicolau DP et al (2003) Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991\u20132000. Clin Infect Dis 37:1643\u20131648","journal-title":"Clin Infect Dis"},{"key":"3582_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jama.293.8.949","volume":"293","author":"TM Hooton","year":"2005","unstructured":"Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE (2005) Amoxicillin-clavulanate vs. ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 293:949\u2013955","journal-title":"JAMA"},{"key":"3582_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jama.2012.80","volume":"307","author":"TM Hooton","year":"2012","unstructured":"Hooton TM, Roberts PL, Stapleton AE (2012) Cefpodoxime vs. ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 307:583\u2013589","journal-title":"JAMA"},{"key":"3582_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J et al (2015) Ceftolazone-tazobactam compared with levofloxacin in treatment of complicated urinary-tract infections, including pyelonephritis: a randomized, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949\u20131956","journal-title":"Lancet"},{"key":"3582_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/jac\/dkw035","volume":"71","author":"AL Hobbs","year":"2016","unstructured":"Hobbs AL, Shea KM, Daley MJ et al (2016) Are first-generation cephalosporins obsolete? A retrospective, non-inferiority, cohort study comparing empirical therapy with cefazolin versus ceftriaxone for acute pyelonephritis in hospitalized patients. J Antimicrob Cemother 71:1665\u20131671","journal-title":"J Antimicrob Cemother"},{"key":"3582_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12879-015-1282-4","volume":"15","author":"O Fasugba","year":"2015","unstructured":"Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G (2015) Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC Infect Dis 15:545","journal-title":"BMC Infect Dis"},{"key":"3582_CR9","unstructured":"FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects (2018). \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm511530.htm\n                    \n                  . Accessed 25 July 2018"},{"issue":"12","key":"3582_CR10","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1086\/652861","volume":"50","author":"BA Lipsky","year":"2010","unstructured":"Lipsky BA, Byren I, Hoey CT (2010) Treatment of bacterial prostatitis. Clin Infect Dis 50(12):1641\u20131652","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3582_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2014.303","volume":"311","author":"L Mody","year":"2014","unstructured":"Mody L, Juthani-Mehta M (2014) Urinary tract infections in older women: a clinical review. JAMA 311(8):844\u2013854","journal-title":"JAMA"},{"key":"3582_CR12","unstructured":"Clinical and Laboratory Standards Institute (2016) Performance standards for antimicrobial susceptibility testing: twenty sixth informational supplement M100S. CLSI, Wayne, PA, USA, 2016"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03582-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03582-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03582-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T14:32:38Z","timestamp":1567089158000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03582-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["3582"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03582-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"11 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance to ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a retrospective study that has been reviewed by the institutional review board prior (IRB) to the beginning of the study. A letter from the IRB has been attached in the supplementary section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required for this study as it was a retrospective study and no interventions were taken that would impact patient care. In addition, informed consent was not required according to per institutional policies and no identifying details were revealed regarding patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declarations"}}]}}